ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Protective effect of aromadendrin against monoiodoacetate-induced osteoarthritis in rats via modulation of TLR4/MyD88/NF-κB, HO-1/Nrf2, and Bcl-2/Caspase-3 signaling pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a long-term chronic, progressive degenerative joint disease characterized via cartilage degradation, subchondral bone remodeling and synovial inflammation, finally leading to joint dysfunction and pain. Aromadendrin, a natural flavonoid has been reported to possess potent antioxidant and anti-inflammatory effect in different pathological conditions. This current study investigates the protective effects of aromadendrin against monoiodoacetate (MIA)-induced OA in rats and explore the underlying mechanism. OA was induced in the rodent via intra-articular administration of MIA (3 mg/50 µL sterile saline), following OA induction, the rats received the oral administration of aromadendrin and diclofenac sodium for 8 weeks. Body weight and joint diameter were estimated at regular intervals. Metabolic parameters such as food intake, water intake, urine output, and fecal output, were monitored throughout the study. End of the study, bone metabolism markers, antioxidant parameters, hepatic, non-hepatic parameters, inflammatory cytokines, inflammatory parameters, apoptosis parameters, and mRNA expression were estimated. Aromadendrin significantly improved the body weight and suppressed the joint diameters at different time intervals (week 2, 4, 6, and 8). Aromadendrin significantly suppressed the level of bone parameters such as COMP, CTX-II, aggrecan, and collagen type II. Aromadendrin altered the food intake, water intake, urine output, fecal output along with oxidative stress (MDA, SOD, CAT, GSH, GPx); inflammatory cytokines (TNF-α, IL-1β, IL-4, IL-6, IL-10, IL-18); inflammatory parameters (COX-2, iNOS, PGE2, NF-κB); apoptosis parameters (Bax. Bcl-2, caspase-3) and MMP level (MMP-1, MMP-2, MMP-3, MMP-9). Aromadendrin significantly altered the mRNA expression of HO-1, Nrf
Indexed as
Identifiers
41524777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.